Medicament dispensing stent for prevention of restenosis of a blood vessel

• US 5,419,760 A
• Filed: 10/11/1994
• Issued: 05/30/1995
• Est. Priority Date: 01/08/1993
• Status: Expired due to Fees

• Current Assignee: PDT Systems Incorporated
• Original Assignee: PDT Systems Incorporated
• Inventors: Narciso, Hugh L. Jr.
• Primary Examiner(s): RIMELL, SAMUEL G
• Application Number:
  US08/320,779
• Time in Patent Office: 231 Days
• Field of Search: 604/8, 604/9, 604/10, 604/21, 606/154, 606/194, 623/1
• US Class Current: 604/8
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2210/0019 operated at only one temperature whilst inside or touching the human body, e.g. constrained in a non-operative shape during surgery, another temperature only occurring before the operation
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 31/042 Polysaccharides
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 1/08 Cellulose derivatives
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin

Abstract

Following recanalization of a stenotic blood vessel, a photosensitizer is administered by means of a vaso-absorbable stent to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of 5-18 days, the period in which cell proliferation can occur. The Vaso-Absorbable Stent (VAST) is described along with the method for its use in Photoatherolytic (PAL) Therapy. The VAST device is used post cardiovascular intervention to: a) deliver a series of drugs to prevent cell proliferation leading to restenosis; and, (b) maintain the patency of the treated vessel and prevent elastic recoil of the vessel by providing support for the vessel wall; and c) deliver and maintain a level of photosensitizer to the treatment site which inhibits smooth muscle cell proliferation and, when activated by light energy, induces cell lysis. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles.

Claims

1. An intravascular stent having a medicament containing portion which disintegrates following implantation within a blood vessel and wherein the disintegration of said medicament containing portion is operable for the contemporaneous release of medicament from said medicament containing portion of said stent and wherein the medicament is a smooth muscle cell proliferation inhibitor which is substantially completely released from said medicament containing portion within 15 days following implantation of said stent within the blood vessel.